HC Wainwright Lowers Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Gossamer Bio in a research report issued to clients and investors on Wednesday, August 26th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their previous forecast of ($0.04). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.02) EPS, Q2 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.09) EPS and FY2029 earnings at ($0.03) EPS.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.04. The company had revenue of $9.24 million during the quarter, compared to analysts’ expectations of $3.63 million.

GOSS has been the topic of several other reports. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target on the stock in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gossamer Bio in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Gossamer Bio currently has a consensus rating of “Hold” and an average target price of $3.20.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $0.17 on Friday. The company has a market cap of $39.92 million, a P/E ratio of -0.24 and a beta of 2.04. Gossamer Bio has a one year low of $0.11 and a one year high of $3.87. The business’s 50-day simple moving average is $0.17 and its 200 day simple moving average is $0.41.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in shares of Gossamer Bio by 22.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after acquiring an additional 4,771 shares in the last quarter. Deutsche Bank AG increased its position in shares of Gossamer Bio by 0.4% during the fourth quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after acquiring an additional 5,414 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Gossamer Bio by 52.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after acquiring an additional 8,239 shares in the last quarter. CWM LLC lifted its stake in shares of Gossamer Bio by 35.7% in the fourth quarter. CWM LLC now owns 33,957 shares of the company’s stock worth $105,000 after acquiring an additional 8,940 shares in the last quarter. Finally, Cerity Partners LLC boosted its holdings in Gossamer Bio by 39.7% in the fourth quarter. Cerity Partners LLC now owns 31,914 shares of the company’s stock valued at $99,000 after purchasing an additional 9,075 shares during the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.